DUBLIN-3: microtubule-binding agent plinabulin in later lines
DUBLIN-3: microtubule-binding agent plinabulin i
ATALANTE-1: anti-cancer vaccination after IO failure
ATALANTE-1: anti-cancer vaccination after IO fai
Gradual progress in the management of mesothelioma and thymoma
Gradual progress in the management of mesothelio
Malignant pleural mesothelioma: immunotherapy-based approaches in all treatment lines
Malignant pleural mesothelioma: immunotherapy-ba
Small-cell lung cancer: on the road to improved efficacy and tolerability
Small-cell lung cancer: on the road to improved
Immunotherapy: boosting efficacy and overcoming resistance
Immunotherapy: boosting efficacy and overcoming
Innovative and established agents across a range of targets
Innovative and established agents across a range
Expansion of treatments and insights in the early-stage disease setting
Expansion of treatments and insights in the earl
Preface
Preface – ESMO 2021 Alex A. Adjei, MD,
